Benitec Biopharma annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Benitec Biopharma R&D Spending Growth & History (BNTC)
Benitec Biopharma's r&d spending was $18.3M for fiscal 2025.
View full Benitec Biopharma company overviewBenitec Biopharma annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $18.3M | $2.7M | +17.45% |
| 2024 | 2024-06-30 | $15.6M | $2.8M | +22.19% |
| 2023 | 2023-06-30 | $12.8M | $1.5M | +13.33% |
| 2022 | 2022-06-30 | $11.3M | $4.3M | +60.57% |
| 2021 | 2021-06-30 | $7.0M | $4.0M | +133.92% |
| 2020 | 2020-06-30 | $3.0M | −$1.6M | −34.29% |
| 2019 | 2019-06-30 | $4.6M | — | — |
Benitec Biopharma quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $6.3M | −$197,000 | −3.03% |
| Q2 2026 | 2025-12-31 | $5.8M | $449,000 | +8.34% |
| Q1 2026 | 2025-09-30 | $3.4M | −$215,000 | −6.00% |
| Q4 2025 | 2025-06-30 | $2.9M | −$645,000 | −18.37% |
| Q3 2025 | 2025-03-31 | $6.5M | $3.9M | +153.12% |
| Q2 2025 | 2024-12-31 | $5.4M | $283,000 | +5.55% |
| Q1 2025 | 2024-09-30 | $3.6M | −$844,000 | −19.06% |
| Q4 2024 | 2024-06-30 | $3.5M | $326,000 | +10.23% |
| Q3 2024 | 2024-03-31 | $2.6M | −$601,000 | −18.98% |
| Q2 2024 | 2023-12-31 | $5.1M | $1.3M | +35.66% |
| Q1 2024 | 2023-09-30 | $4.4M | $1.8M | +66.50% |
| Q4 2023 | 2023-06-30 | $3.2M | $11,000 | +0.35% |
| Q3 2023 | 2023-03-31 | $3.2M | $996,000 | +45.88% |
| Q2 2023 | 2022-12-31 | $3.8M | $615,000 | +19.55% |
| Q1 2023 | 2022-09-30 | $2.7M | −$120,000 | −4.32% |
| Q4 2022 | 2022-06-30 | $3.2M | $855,000 | +36.85% |
| Q3 2022 | 2022-03-31 | $2.2M | −$587,000 | −21.28% |
| Q2 2022 | 2021-12-31 | $3.1M | $2.0M | +169.35% |
| Q1 2022 | 2021-09-30 | $2.8M | $2.0M | +259.17% |
| Q4 2021 | 2021-06-30 | $2.3M | $1.1M | +97.61% |
| Q3 2021 | 2021-03-31 | $2.8M | $2.0M | +242.61% |
| Q2 2021 | 2020-12-31 | $1.2M | $569,000 | +94.99% |
| Q1 2021 | 2020-09-30 | $774,000 | $351,000 | +82.98% |
| Q4 2020 | 2020-06-30 | $1.2M | — | — |
| Q3 2020 | 2020-03-31 | $805,000 | — | — |
| Q2 2020 | 2019-12-31 | $599,000 | — | — |
| Q1 2020 | 2019-09-30 | $423,000 | — | — |
Benitec Biopharma r&d spending trends
Over the last five fiscal years, Benitec Biopharma's r&d spending increased from $3.0M to $18.3M, a change of $15.3M. The latest reported quarter, Q3 2026, shows $6.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Benitec Biopharma source filings ↗